Tailored therapies for triple-negative breast cancer: current landscape and future perceptions
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025-08 · 398 (8) · 9425-9450
DOI: 10.1007/s00210-025-03896-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 03.03.2025. Verfasst von Yumna Khan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biotechnology and Genetic Engineering, The University of Agriculture, Peshawar, 25130, Pakistan. yumnakhan4514@gmail.com. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Precision Medicine. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 195 Literaturangaben.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) has become one of the most challenging cancers to date due to its great variability in biological features, high growth rate, and rare options for treatment. This review examines several innovative strategies for tailored treatment of TNBC, focusing mainly on the most recent developments and potential directions. The molecular landscape of TNBC is covered in the first section, which keeps the focus on transcriptome and genomic profiling while highlighting key molecular targets like mutations in the BRCA1/2, PIK3CA, androgen receptors (AR), epidermal growth factor receptors (EGFR), and immunological checkpoint molecules. This review also covers novel therapies that aim to block well-defined pathways, including immune checkpoint inhibitors (ICI), EGFR inhibitors, drugs that target AR, poly ADP ribose polymerase (PARP) inhibitors, and drugs that disrupt the PI3K/AKT/mTOR pathway. Additionally, it covers novel strategies focusing on combination therapy, targeting the DNA damage response pathway, and epigenetic modulators. Conclusively, it emphasizes perspectives and directions on topics such as personalized medicine, artificial intelligence (AI), predictive biomarkers, and treatment planning with the inclusion of machine learning (ML).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biotechnology and Genetic Engineering, The University of Agriculture, Peshawar, 25130, Pakistan. yumnakhan4514@gmail.com.
- Bakhtawar Amin Medical and Dental College, Bakhtawar Amin Trust Teaching Hospital, Multan, Pakistan.
- Department of Veterinary Microbiology, Faculty of Veterinary Medicine, Ataturk University, Erzurum, Turkey.
- Abbottabad International Medical Institute, Abbottabad, 22020, Pakistan.
- Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, Uttarakhand, 248007, India.
- Institute of Biotechnology and Genetic Engineering, The University of Agriculture, Peshawar, 25130, Pakistan.
ORCID-Profile: Doha El-Sayed Ellakwa
Zitieren
APA
Khan, Y., Rizvi, S., Raza, A., Khan, A., Hussain, S., Khan, N. U., Alshammari, S. O., Alshammari, Q. A., Alshammari, A., & Ellakwa, D. E. (2025). Tailored therapies for triple-negative breast cancer: current landscape and future perceptions. Naunyn-Schmiedeberg's Archives of Pharmacology, 398(8), 9425-9450. https://doi.org/10.1007/s00210-025-03896-4
Vancouver
Khan Y, Rizvi S, Raza A, Khan A, Hussain S, Khan NU, et al. Tailored therapies for triple-negative breast cancer: current landscape and future perceptions. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025;398(8):9425-9450. doi:10.1007/s00210-025-03896-4
BibTeX
@article{Khan2025,
author = {Khan, Yumna and Rizvi, Sana and Raza, Ali and Khan, Amna and Hussain, Sadique and Khan, Najeeb Ullah and Alshammari, Saud O and Alshammari, Qamar A and Alshammari, Abdulkarim and Ellakwa, Doha El-Sayed},
title = {Tailored therapies for triple-negative breast cancer: current landscape and future perceptions},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
volume = {398},
number = {8},
pages = {9425--9450},
doi = {10.1007/s00210-025-03896-4}
}
EUVIMED